Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Mycosis fungoides Indication Strategy Report 2026: CCR4, Trials and Deals
23 July 2026
2026 Mycosis fungoides strategy: epidemiology, CCR4 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Cutaneous T-cell lymphoma Indication Strategy Report 2026: CCR4, Trials and Deals
23 July 2026
2026 Cutaneous T-cell lymphoma strategy: epidemiology, CCR4 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Vulvovaginal melanoma Indication Strategy Report 2026: c-Kit, Trials and Deals
23 July 2026
2026 Vulvovaginal melanoma strategy: epidemiology, c-Kit biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Uterine carcinosarcoma Indication Strategy Report 2026: HER2, Trials and Deals
23 July 2026
2026 Uterine carcinosarcoma strategy: epidemiology, HER2 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Ovarian carcinosarcoma Indication Strategy Report 2026: HER2, Trials and Deals
23 July 2026
2026 Ovarian carcinosarcoma strategy: epidemiology, HER2 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Fallopian tube cancer Indication Strategy Report 2026: FOLR1, Trials and Deals
23 July 2026
2026 Fallopian tube cancer strategy: epidemiology, FOLR1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Primary peritoneal cancer Indication Strategy Report 2026: FOLR1, Trials and Deals
23 July 2026
2026 Primary peritoneal cancer strategy: epidemiology, FOLR1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
HER2-low breast cancer Indication Strategy Report 2026: HER2, Trials and Deals
23 July 2026
2026 HER2-low breast cancer strategy: epidemiology, HER2 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
6 min read
Zaltenibart Biologics Sequence Review Report 2026: MASP-3 Similarity and Patent-Risk Signals
23 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zaltenibart, an antibody targeting MASP-3.
Latest Hotspot
6 min read
Vipalanebart Biologics Sequence Review Report 2026: ADCYAP1 Similarity and Patent-Risk Signals
23 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vipalanebart, an antibody targeting ADCYAP1.
Latest Hotspot
6 min read
Verekitug Biologics Sequence Review Report 2026: CRLF2 Similarity and Patent-Risk Signals
23 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Verekitug, an antibody targeting CRLF2.
Latest Hotspot
6 min read
Venanprubart Biologics Sequence Review Report 2026: BTLA Similarity and Patent-Risk Signals
23 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Venanprubart, an antibody targeting BTLA.